Concerns about a portion of the study supporting a proposal for an Rx-to-OTC switch of 0.075-mg norgestrel as a daily oral contraceptive in the US have prompted the Food and Drug Administration to ask an advisory panel to recommend a better study.
In addition to asking whether the Nonprescription Drug and the Obstetrics, Reproductive and Urologic Drugs advisory committees, during a joint...







